Is Duvelisib a targeted drug?

Duvelisib is a targeted drug. It belongs to the PI3K inhibitors (Phosphoinositide 3-kinase inhibitors) category and is mainly used to treat some specific types of lymphoma. Here are some key pieces of information about duvelised as a targeted agent:

1.PI3KInhibition: PI3K is an enzyme involved in a variety of biological processes within cells, including cell growth, differentiation, survival and metabolism. PI3KThe signaling pathway plays an important role in both normal cells and cancer cells. The main mechanism of action of duveliced u200bu200bis to inhibit multiple isoforms in the PI3K signaling pathway, including the delta type and the γ type.

2.Multi-target effects: It is worth noting that duveliced is a multi-target inhibitor, which means that it can interfere with multiple branches in the PI3K signaling pathway at the same time, thereby affecting multiple biological processes. This makes it an effective targeted drug that can interfere with the growth and spread of cancer cells.

3.For specific types of lymphoma: Duvelisel is commonly used to treat certain types of lymphoma, such as adult T-cell leukemia lymphoma/lymphoma cell leukemia (ATLL/CTCL) and relapsed smallB-cell lymphoma. These diseases are usually related to abnormalities in the PI3K signaling pathway. Duveliside can interfere with this pathway, thereby slowing or inhibiting the growth of tumor cells.

4.Therapeutic prospects: Targeted drugs such as duveliside represent an important advance in the field of cancer treatment. It has a more precise mechanism of action that generally corresponds to fewer toxic side effects, making it a promising treatment, especially for certain types of cancer.

The original drug of Duvelisel Capsules has been launched in China, but it is not covered by medical insurance. Patients can buy it domestically at a price of more than 20,000 yuan. For specific prices, please consult the local hospital pharmacy.